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Hospital-based use of
thromboprophylaxis in
patients with COVID-19
Physicians are receiving a great deal
of information regarding how to care
for patients with coronavirus disease
2019 (COVID-19). We would like
to offer further information about
thromboprophylaxis that we believe
is worth considering when treating
patients who have been admitted to
hospital with COVID-19.
Tang and colleagues1 described a
consecutive series of 183 patients
who had been admitted to hospital
with COVID-19 in China. Activation
of the coagulation system was found
in many patients, and the degree of
activation (defined as, for example,
increased D-dimer concentrations at
time of admission) was significantly
higher in patients who did not
survive than those who did survive.
Overall, 21 (11%) of 183 patients died.
15 (71%) of 21 non-survivors and
only one (1%) of 162 survivors met
criteria for disseminated intravascular
coagulation during their hospital stay.
In a case series from China,2 increased
D-dimer concentration at time of
admission to hospital (>1 µg/mL) was
associated with a risk of in-hospital
mortality that was 18 times higher than
among those with normal D-dimer
concentrations, and the authors high
lighted that “inadequate adherence to
standard supportive therapy”, among
other things, might have led to poor
outcomes in some patients.2
Acutely ill patients with severe viral
pneumonia and acute respiratory
distress syndrome (ARDS), such as
those with H1N1 infection, who have
been admitted to hospital have a
23-times increased risk for pulmonary
embolism,3 and guidelines support
routine thromboprophylaxis in
these patients.4 Increased D-dimer
concentrations of more than double
the upper limit of normal has emerged
as a new biomarker to predict risk
of venous thromboembolism in all
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patients in hospitals. Trial subgroup
analyses, in which increased D-dimer
concentration or admission to hospital
with infection (particularly pneumonia)
were incorporated as variables, show
that extended thromboprophylaxis
with direct oral anticoagulants has
benefit compared with routine inhospital thromboprophylaxis with low
molecular weight heparin.5 Finally,
empirical anticoagulation has been
associated with improved thrombotic
event-free survival in critically ill
patients with ARDS due to influenza A
H1N1.3
In light of this evidence, and the
fact that hospitals might soon have
a large number of patients with
COVID-19 who might meet guideline
requirements for thromboprophylaxis,
we believe it seems prudent to use
thromboprophylaxis in such patients,
particularly those with evidence of
activation of the coagulation system
(eg, increased D-dimer concentrations)
on admission.
Of utmost importance will be
the prospective, real-time data
collection to assess whether use of
thromboprophylaxis in patients with
COVID-19 leads to improved outcomes,
including improved survival, without
clinically important bleeding.
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